1. Detection and comparison of SARS-CoV-2 antibody produced in naturally infected patients and vaccinated individuals in Addis Ababa, Ethiopia: multicenter cross-sectional study
- Author
-
Chala Bashea, Addisu Gize, Tadesse Lejisa, Demiraw Bikila, Betselot Zerihun, Feyissa Challa, Daniel Melese, Alganesh Gebreyohanns, Kasahun Gorems, Solomon Ali, Gadissa Bedada Hundie, Habteyes Hailu Tola, and Wondewosen Tsegaye
- Subjects
COVID-19 ,SARS-CoV-2 ,Vaccine ,Virology ,Immunology ,anti-SARS-CoV-2 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or vaccination triggers antibody production against key viral antigens. However, there is limited evidence on the levels of antibodies produced in naturally infected individuals compared to those vaccinated in Ethiopia. Therefore, we aimed to detect and compare SARS-CoV-2 antibodies produced by naturally infected and vaccinated individuals. Materials and methods We conducted a multicenter cross-sectional study among a total of 355 naturally infected and 355 vaccinated individuals from November 2022 to April 2023 at 10 selected health facilities in Addis Ababa, Ethiopia. We enrolled the participants consecutively upon their arrival at health facilities until the required sample size was achieved. We used a structured questionnaire to collect data on the demographic and clinical characteristics of the participants. We also collected 3–5 ml of blood samples from all participants and tested for anti-Spike (anti-S) and anti-nucleocapsid (anti-N) antibodies using Cobas 6000. We utilized frequency, mean, or median to describe the data, the Mann-Whitney U test to compare groups, and a generalized linear regression model to assess factors associated with anti-S antibody concentration. We analyzed the data with SPSS version 26, and the level of significance was set at P-value
- Published
- 2024
- Full Text
- View/download PDF